Deborah J. Wexler, MD, MSc, and colleagues reviewed recent shifts in diabetes care, such as SGLT2i and GLP-1 RA medications.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — New recommendations from ACP on type 2 diabetes treatment include adding a GLP-1 agonist or SGLT-2 ...

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...

Learn about the current medication options for managing type 2 diabetes and chronic kidney disease, including SGLT2 inhibitors, GLP-1 receptor agonists, and more.

When it comes to kidney and cardiovascular outcomes, there is no significant difference between treatment with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes, according ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...